動物胃食道逆流症市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球動物胃食道逆流症市場價值為 31 億美元，預計到 2034 年將以 7.5% 的複合年成長率成長，達到 63 億美元，這得益於伴侶動物和牲畜中 GERD 患病率的不斷上升，以及獸醫診斷和治療技術的進步。人口老化、肥胖和胃腸道感染等因素導致動物患有 GERD，對有效治療方案的需求增加。該市場的特點是擁有各種診斷工具和治療干預措施，包括制酸劑、H2 拮抗劑和質子幫浦抑制劑，這些藥物在獸醫學中廣泛用於控制 GERD 症狀。這些藥物有助於減少胃酸，並且由於其在動物身上的安全性和有效性得到證實而成為常用處方藥。

此外，獸醫診斷技術的進步，例如內視鏡成像、先進的血液檢測和超音波技術，使獸醫能夠更早、更準確地檢測胃食道逆流症 (GERD)。這促進了早期介入策略的推廣，從而顯著改善治療效果並減少長期併發症。寵物主人對消化系統疾病對寵物整體健康影響的認知不斷提高，也加速了對非處方藥和處方藥的需求。

2024年，動物胃食道逆流症（GERD）市場的治療領域產值達17億美元。制酸劑、H2拮抗劑和質子幫浦抑制劑等藥物已被證明能夠持續有效地降低動物胃酸水平，這對於控制GERD症狀至關重要。這些藥物廣泛用於人用和獸用製劑，由於其安全性和極低的副作用，多年來一直被用於獸藥。

2024年，伴侶動物細分市場佔最大佔有率，達71.7%。寵物肥胖率不斷上升，導致許多伴侶動物營養不良。飲食問題常常導致胃酸逆流，增加了對胃食道逆流（GERD）治療方案的需求。某些犬種，例如哈巴狗、鬥牛犬和拳師犬，由於其獨特的解剖特徵，特別容易患上GERD。

由於寵物飼養數量的增加以及獸醫服務需求的不斷成長，美國動物胃食道逆流症市場在2024年的價值達到12億美元。寵物主人和牲畜飼養者越來越意識到胃腸道健康的重要性及其對動物整體福祉的影響。政府在疾病預防和動物福利方面的措施進一步支持了市場的成長。

全球動物胃食道逆流症市場的主要參與者包括勃林格殷格翰、碩騰、默克、禮來、希爾思寵物營養、愛德士實驗室、嘉里集團、Vetcare、Vetoquinol 和維克。這些公司積極參與開發並提供一系列診斷和治療解決方案，以應對動物胃食道逆流症 (GERD)。他們的努力旨在改善受影響動物的生活品質，並滿足獸醫行業對有效治療日益成長的需求。為了鞏固市場地位，動物胃食道逆流症 (GERD) 市場的公司正在採取各種策略。他們專注於研發，以推出創新的診斷工具和治療方案。他們正在與獸醫診所和研究機構合作，以增強產品供應並擴大市場覆蓋範圍。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 動物胃腸道疾病盛行率不斷上升
    • 動物健康意識不斷提高
    • 診斷工具的技術進步
    • 增加寵物擁有量和寵物人性化
  • 產業陷阱與挑戰
    • 監管挑戰和可靠性問題
    • 內視鏡和pH監測程序成本高昂
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供應方影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 診斷
  • 測試類型
    • 實驗室檢查
    • 獸醫影像
    • 其他診斷測試
  • 最終用途
    • 獸醫醫院和診所
    • 獸醫診斷中心
    • 其他最終用途
• 治療
  • 藥品類別
    • 抗酸藥
    • H2受體阻斷劑
    • 質子幫浦抑制劑（PPI）
    • 促動力劑
    • 其他藥物類別
  • 給藥途徑
    • 口服
    • 注射劑

第6章：市場估計與預測：依動物類型，2021 - 2034 年

• 主要趨勢
• 伴侶動物
• 牲畜

第7章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第8章：公司簡介

• Boehringer Ingelheim
• Daiichi Sankyo
• Elanco Animal Health
• Hill's Pet Nutrition
• IDEXX Laboratories
• Kerry Group
• Merck
• Vetcare
• Vetoquinol
• Vibrac
• Zoetis

The Global Animal Gastroesophageal Reflux Disease Market was valued at USD 3.1 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 6.3 billion by 2034, driven by the increasing prevalence of GERD among both companion and livestock animals, as well as advancements in veterinary diagnostics and treatments. Factors such as aging populations, obesity, and gastrointestinal infections contribute to the development of GERD in animals, leading to a higher demand for effective treatment options. The market is characterized by the availability of various diagnostic tools and therapeutic interventions, including antacids, H2 antagonists, and proton pump inhibitors, which are widely used in veterinary medicine to manage GERD symptoms. These medications help reduce stomach acid and are commonly prescribed due to their proven safety and efficacy profiles in animals.

In addition, advancements in veterinary diagnostics, such as endoscopic imaging, advanced blood panels, and ultrasound technologies, are making it easier for veterinarians to detect GERD earlier and with greater precision. This has led to an uptick in early intervention strategies, which can significantly improve outcomes and reduce long-term complications. The increasing awareness among pet owners about the impact of digestive disorders on overall pet health is also accelerating demand for both over-the-counter and prescription solutions.

The treatment segment in the animal gastroesophageal reflux disease market generated USD 1.7 billion in 2024. Medications such as antacids, H2 antagonists, and proton pump inhibitors have shown consistent effectiveness in reducing stomach acid in animals, which is crucial for controlling GERD symptoms. These medications are widely available in both human and veterinary formulations and have been used in veterinary medicine for years due to their safety and minimal side effects.

The companion animals segment held the largest share of 71.7% in 2024. Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. Dietary issues often lead to the development of acid reflux, increasing the need for GERD treatment options. Certain dog breeds, such as pugs, bulldogs, and boxers, are particularly susceptible to GERD due to their unique anatomical features.

United States Animal Gastroesophageal Reflux Disease Market was valued at USD 1.2 billion in 2024, owing to the increasing number of pet ownership and the growing demand for veterinary services. There is a rising awareness among pet owners and livestock breeders regarding the importance of gastrointestinal health and its impact on overall animal well-being. Government initiatives focusing on disease prevention and animal welfare further support market growth.

Key players in the Global Animal Gastroesophageal Reflux Disease Market include Boehringer Ingelheim, Zoetis, Merck, Elanco, Hill's Pet Nutrition, IDEXX Laboratories, Kerry Group, Vetcare, Vetoquinol, and Virbac. These companies are actively involved in developing and offering a range of diagnostic and therapeutic solutions to address GERD in animals. Their efforts aim to improve the quality of life for affected animals and meet the growing demand for effective treatments in the veterinary sector. To strengthen their market position, companies in the animal GERD market are adopting various strategies. They are focusing on research and development to introduce innovative diagnostic tools and treatment options. Collaborations with veterinary clinics and research institutions are being pursued to enhance product offerings and expand market reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal diseases in animals
    • 3.2.1.2 Rising awareness of animal health
    • 3.2.1.3 Technological advancements in diagnostic tools
    • 3.2.1.4 Increased pet ownership and pet humanization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory challenges and reliability concerns
    • 3.2.2.2 High cost of endoscopic and pH monitoring procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostics
  • 5.2.1 Test type
    • 5.2.1.1 Laboratory tests
    • 5.2.1.2 Veterinary imaging
    • 5.2.1.3 Other diagnostic tests
  • 5.2.2 End use
    • 5.2.2.1 Veterinary hospital and clinics
    • 5.2.2.2 Veterinary diagnostic centers
    • 5.2.2.3 Other end use
• 5.3 Treatment
  • 5.3.1 Drug class
    • 5.3.1.1 Antacids
    • 5.3.1.2 H2 receptor blockers
    • 5.3.1.3 Proton pump inhibitors (PPIs)
    • 5.3.1.4 Pro-kinetic agents
    • 5.3.1.5 Other drug classes
  • 5.3.2 Route of administration
    • 5.3.2.1 Oral
    • 5.3.2.2 Injectables

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
• 6.3 Livestock animals

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Boehringer Ingelheim
• 8.2 Daiichi Sankyo
• 8.3 Elanco Animal Health
• 8.4 Hill's Pet Nutrition
• 8.5 IDEXX Laboratories
• 8.6 Kerry Group
• 8.7 Merck
• 8.8 Vetcare
• 8.9 Vetoquinol
• 8.10 Vibrac
• 8.11 Zoetis